Neuroprotective Effects of Cistanches Herba Therapy on Patients with Moderate Alzheimer’s Disease

Figure 4

T-tau, TNF-α, and IL-1β protein levels in the CSF of AD patients measured by Western blot. Protein levels of T-tau (a), TNF-α (b) and IL-1β (c) from AD patients’ CSF, and (d) β-actin. 1: DON treatment group; 2: CH treatment group; 3: control group. For (e)–(g) the relative changes in protein content of T-tau, TNF-α, and IL-1β. The contents of T-tau, TNF-α, and IL-1β had decreased during 48 weeks compared with control group after drug treatments (). There was no statistical deviation between DON treatment group and CH treatment group ().

(a)

(b)

(c)

(d)

(e)

(f)

(g)